KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accumulated Expenses (2016 - 2019)

Biomarin Pharmaceutical's Accumulated Expenses history spans 10 years, with the latest figure at $46.1 million for Q1 2019.

  • For the quarter ending Q1 2019, Accumulated Expenses fell 39.81% year-over-year to $46.1 million, compared with a TTM value of $46.1 million through Mar 2019, down 39.81%, and an annual FY2018 reading of $20.0 million, down 85.81% over the prior year.
  • Accumulated Expenses for Q1 2019 was $46.1 million at Biomarin Pharmaceutical, up from $20.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $140.8 million in Q4 2017, with the low at $9.5 million in Q2 2015.
  • Average Accumulated Expenses over 5 years is $51.4 million, with a median of $34.7 million recorded in 2016.
  • Year-over-year, Accumulated Expenses surged 1653.7% in 2015 and then tumbled 85.81% in 2018.
  • Tracing BMRN's Accumulated Expenses over 5 years: stood at $95.3 million in 2015, then plummeted by 63.57% to $34.7 million in 2016, then skyrocketed by 305.28% to $140.8 million in 2017, then tumbled by 85.81% to $20.0 million in 2018, then surged by 130.81% to $46.1 million in 2019.
  • Per Business Quant, the three most recent readings for BMRN's Accumulated Expenses are $46.1 million (Q1 2019), $20.0 million (Q4 2018), and $19.3 million (Q3 2018).